# Venture Investors

> Venture Investors is a VC fund backing Health Care and Biotechnology. See 109 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Madison, United States
- Total investments: 109
- Last investment: Nov 2025
- Lead investor: 51%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/venture-investors/
- X (Twitter): https://www.twitter.com/vi_funds
- Website: http://www.ventureinvestors.com

Venture Investors is a VC fund in Madison focused on Health Care and Biotechnology. Turning innovation into health. Venture Investors seeks the next big things in healthcare. Based in the Midwest with open access to renowned research universities, and the vibrant communities that surround them, we target, uncover, and invest in extraordinary ideas that will shape the future of health and wellness. With decades of proven success,we’re fueling the future of what’s driving healthcare. Today, we have over $200 million in assets under management.

## Contacts

5 contacts available for Venture Investors. Shizune tracks 9 team members at Venture Investors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/venture-investors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 32 | 29% |
| Biotechnology | 29 | 27% |
| Medical | 16 | 15% |
| Medical Device | 15 | 14% |
| Therapeutics | 9 | 8% |

62 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 31 | 28% |
| Series B | 21 | 19% |
| Funding Round | 15 | 14% |
| Series C | 11 | 10% |
| Seed | 5 | 5% |

12 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Becky Hoerman | Controller | 0 | https://shizune.co/investors/profile/becky-gering |
| David Arnstein | Chief Financial Officer and Managing Director | 0 | https://shizune.co/investors/profile/david-arnstein |
| Jake Simon | Principal Venture Partner | 1 | https://shizune.co/investors/profile/jake-simon |
| Jim Adox | Managing Director | 20 | https://shizune.co/investors/profile/jim-adox |
| John Neis | Managing Director | 17 | https://shizune.co/investors/profile/john-neis |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Elephas | Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodalmicroscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development. | $40M | Venture - Series Unknown | Nov 06, 2025 |  |
| HistoSonics | HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. |  | Private Equity | Aug 07, 2025 |  |
| EnsoData | EnsoData is a startup that utilizes artificial intelligence to analyze the human body to diagnose health conditions. EnsoData, whose software uses machine learning algorithms to help clinicians score sleep data and diagnose patients with sleep apnea and other disorders, has now realized that dream—and then some. EnsoData's autoscoringalgorithm combines AASM scoring best practices with cutting edge machine learning algorithms that learn and adapt to every single patient. | $20M | Series B | Jun 25, 2025 |  |
| Rivermark Medical | Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function. Developed by urologists to reliably reduce BPH symptoms with minimal side effects. | $3M | Venture - Series Unknown | Jun 04, 2025 |  |
| Ten Bay Bio | Ten Bay Bio is a biotechnology company that offers biological therapies for treatment of complex diseases in immunology. | $500K | Venture - Series Unknown | Jun 04, 2025 |  |
| Sanacor | Sanacor wants to create a remedy for persistent inflammation in the heart. | $500K | Seed | Jun 04, 2025 |  |
| Rivermark Medical | Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function. Developed by urologists to reliably reduce BPH symptoms with minimal side effects. | $30M | Series C | Oct 10, 2024 |  |
| HistoSonics | HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $102M | Series D | Aug 15, 2024 |  |
| EarliTec Diagnostics | EarliTec Diagnostics is a digital health company making earlier identification and treatment for ASD and related disabilities accessible to children everywhere. Developed by leading researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine and Yale University, EarliTec is pioneering development of biomarkers that helpparents, providers and caregivers understand how a child is viewing the world. | $21.5M | Series B | Apr 02, 2024 |  |
| ViaLase | ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. The company's system focuses on the development of micron-resolution OCT image-guided femtosecond laser technology to create micron-sized customized drainage channels through the trabecular meshwork that connects the anterior chamber to theSchlemm's canal without surgically opening or penetrating the eye, enabling medical professionals to improve glaucoma management with its efficient non-invasive treatment.ViaLase was incorporated in 2019 and is headquartered in Corona Del Mar, California. | $40M | Series C | Apr 01, 2024 |  |

10 of 109 investments shown.

## Co-investors
- [State of Wisconsin Investment Board](https://shizune.co/investors/profile/state-of-wisconsin-investment-board) — VC Fund, 19 deals together
- [Wisconsin Alumni Research Foundation](https://shizune.co/investors/profile/wisconsin-alumni-research-foundation) — VC Fund, 14 deals together
- [Wisconsin Investment Partners](https://shizune.co/investors/profile/wisconsin-investment-partners) — VC Fund, 9 deals together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 7 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 7 deals together
- [Triathlon Medical Venture Partners](https://shizune.co/investors/profile/triathlon-medical-venture-partners) — VC Fund, 7 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Venture Investors invest in?

Venture Investors invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 109 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Venture Investors?

Public channels for Venture Investors include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Venture Investors?

The team at Venture Investors includes Becky Hoerman (Controller), David Arnstein (Chief Financial Officer and Managing Director) and Jake Simon (Principal Venture Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co